Guardant Health Inc’s filing revealed that its Chief Commercial Officer Freeman Chris unloaded Company’s shares for reported $3.24 million on Dec 05 ’25. In the deal valued at $103.07 per share,31,452 shares were sold. As a result of this transaction, Freeman Chris now holds 25,987 shares worth roughly $2.71 million.
Then, Bell Michael Brian sold 80,362 shares, generating $8,288,742 in total proceeds. Upon selling the shares at $103.14, the Chief Financial Officer now owns 28,052 shares.
Before that, CLARK IAN T sold 28,611 shares. Guardant Health Inc shares valued at $3,066,817 were divested by the Director at a price of $107.19 per share. As a result of the transaction, CLARK IAN T now holds 9,851 shares, worth roughly $1.03 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in late September from “a Peer perform” to “an Outperform”. Mizuho started covering the stock on April 10, 2025. It rated GH as “an Outperform”.
Price Performance Review of GH
On Monday, Guardant Health Inc [NASDAQ:GH] saw its stock jump 2.11% to $104.17. Over the last five days, the stock has lost -1.00%. Guardant Health Inc shares have risen nearly 173.34% since the year began. Nevertheless, the stocks have risen 240.98% over the past one year. While a 52-week high of $112.43 was reached on 11/25/25, a 52-week low of $29.91 was recorded on 01/02/25.
Levels Of Support And Resistance For GH Stock
The 24-hour chart illustrates a support level at 102.11, which if violated will result in even more drops to 100.05. On the upside, there is a resistance level at 106.19. A further resistance level may holdings at 108.21.
How much short interest is there in Guardant Health Inc?
A steep rise in short interest was recorded in Guardant Health Inc stocks on 2025-11-14, growing by 0.68 million shares to a total of 8.96 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 8.27 million shares. There was a rise of 7.61%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 23, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
